re: Ann: Vanessa Waddell appointed General Ma...
Ms Waddell has previously been employed in a number of executive management roles in the Australian biotechnology industry, primarily in the oncology therapeutic sector. Previous appointments include Chief Executive Officer of Velacor Therapeutics (private company focussed on oncology and dementia drug development), Director of Operations (venture capital funded oncology drug discovery and development company) and Business Development and Intellectual Property Manager at ASX listed Prima Biomed Limited, which has progressed to Phase III clinical trials of its ovarian cancer therapeutic. Ms Waddell holds a Bachelor of Science with 1st Class Honours in Biochemistry from the University of Sydney, NSW and a Master in Business Administration from Deakin University for which she was awarded the Brookes Scholar Medal for academic excellence in 2006.
HTX Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
